Evidence map›Paper›PMID 36073731›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2023

The Australia Smoking and Vaping Model: The Potential Impact of Increasing Access to Nicotine Vaping Products.

David T Levy, Coral Gartner, Alex C Liber, Luz Maria Sánchez-Romero, Zhe Yuan, Yameng Li, K Michael Cummings, Ron Borland

Open access · hybridAbstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

David T LevyLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.ORCID 0000-0001-5280-3612
Coral GartnerSchool of Public Health, Faculty of Medicine, University of Queensland, Queensland, Australia.ORCID 0000-0002-6651-8035
Alex C LiberLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.ORCID 0000-0001-7863-3906
Luz Maria Sánchez-RomeroLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.ORCID 0000-0001-7951-3965
Zhe YuanLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.
Yameng LiLombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.ORCID 0000-0001-5851-8652
K Michael CummingsDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, USA.
Ron BorlandMelbourne Centre for Behaviour Change, School of Psychological Sciences, University of Melbourne, Melbourne, Australia.ORCID 0000-0003-0059-178X
Georgetown University · USMedical University of South Carolina · USThe University of Melbourne · AUThe University of Queensland · AU

Funding

Vaporized Nicotine Product Initiation Among Youth in the US, Canada, and England: Methods to Predict Uptake and Policy EfficacyP01CA200512 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FONG, GEOFFREY T · 2016 to 2025
$25.3M
NCI NIH HHS P01 CA200512
6 · The paper itself

Abstract

backgroundWe model the potential impact of relaxing current nicotine vaping product (NVP) restrictions on public health in Australia. AIMS AND

methodsA Restricted NVP Scenario was first developed to project current smoking and vaping rates, where a U.S. smoking model was calibrated to recent Australian trends. To model less restrictive NVP policies, a Permissive NVP Scenario applied rates of switching from smoking to vaping, initiation into NVP and cigarette use, and cessation from smoking and vaping based on U.S. trends. The model measures vaping risk relative to the excess mortality rate of smoking. The public health impacts are measured as the difference between smoking- and vaping-attributable deaths (SVADs) and life years lost (LYLs) in the Restricted and Permissive NVP Scenarios. Sensitivity analysis is conducted regarding the NVP excess risk and other factors.

resultsAssuming an NVP excess risk of 5% that of smoking, 104.2 thousand SVADs (7.7% reduction) and 2.05 million LYLs (17.3% reduction) are averted during 2017-2080 in the Permissive NVP Scenario compared to the Restricted NVP Scenario. Assuming 40% NVP excess risk, 70 thousand SVADs and 1.2 million LYLs are averted. The impact is sensitive to the rate at which smokers switch to NVPs and quit smoking, and relatively insensitive to the smoking initiation and NVP initiation and cessation rates.

conclusionsThe model suggests the potential for public health gains to be achieved by relaxing NVP access regulations. However, the model would benefit from better information regarding the impact of NVPs on smoking under a relaxation of current restrictions. IMPLICATIONS: Australia has implemented a strong array of cigarette-oriented policies, but has restricted access to NVPs. The Smoking and Vaping Model offers a framework for modeling hypothetical policy scenarios. The Australian model shows the potential for public health gains by maintaining cigarette-oriented policies while relaxing the current restrictive NVP policy. Modeling results under a permissive NVP policy are particularly sensitive to the estimated rates of smoking cessation and switching to vaping, which are not well established and will likely depend on past and future cigarette-oriented policies and the specific NVP policies implemented in Australia.

Indexed as

Electronic Nicotine Delivery SystemsSmoking CessationVapingAustraliaHumansNicotineSmokingNicotine

Identifiers

PMID36073731
PMCPMC9910149
OpenAlexW4294991917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.